154 related articles for article (PubMed ID: 15095213)
1. Two regimens of azithromycin prophylaxis against community-acquired respiratory and skin/soft-tissue infections among military trainees.
Guchev IA; Gray GC; Klochkov OI
Clin Infect Dis; 2004 Apr; 38(8):1095-101. PubMed ID: 15095213
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy and safety of azithromycin prophylaxis of respiratory tract infections in military community].
Guchev IA; Klochkov OI; Ivanitsa GV; Pervov IuA; Shturmina SM; Rosman SV
Antibiot Khimioter; 2004; 49(8-9):34-5, 37-42. PubMed ID: 15727144
[TBL] [Abstract][Full Text] [Related]
3. Randomized, placebo-controlled clinical trial of oral azithromycin prophylaxis against respiratory infections in a high-risk, young adult population.
Gray GC; Witucki PJ; Gould MT; Bell SJ; Hiliopoulos KM; McKeehan JA; Fuller JM; Barrozo CP; Hudspeth MK; Smith TC; Ledbetter EK; Wallace MR
Clin Infect Dis; 2001 Oct; 33(7):983-9. PubMed ID: 11528569
[TBL] [Abstract][Full Text] [Related]
4. Azithromycin chemoprophylaxis.
Gray GC; Ryan MA
J Infect Dis; 2001 Sep; 184(5):657. PubMed ID: 11494171
[No Abstract] [Full Text] [Related]
5. [The use of azithromycin in prophylaxis of respiratory infections occurred in the organized collectives, clinical sequelae].
Klochkov OI; Guchev IA; Ivanitsa GV
Voen Med Zh; 2004 Nov; 325(11):43-7, 80. PubMed ID: 15675752
[TBL] [Abstract][Full Text] [Related]
6. Pneumonia outbreak associated with group a Streptococcus species at a military training facility.
Crum NF; Russell KL; Kaplan EL; Wallace MR; Wu J; Ashtari P; Morris DJ; Hale BR
Clin Infect Dis; 2005 Feb; 40(4):511-8. PubMed ID: 15712072
[TBL] [Abstract][Full Text] [Related]
7. Clinical implications of macrolide resistance in community-acquired respiratory tract infections.
Hoban DJ; Zhanel GG
Expert Rev Anti Infect Ther; 2006 Dec; 4(6):973-80. PubMed ID: 17181414
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
[TBL] [Abstract][Full Text] [Related]
9. 13--Antibiotic therapy of community-acquired pneumonia (CAP) caused by atypical agents.
Roig J; Casal J; Gispert P; Gea E
Med Mal Infect; 2006; 36(11-12):680-9. PubMed ID: 17095177
[TBL] [Abstract][Full Text] [Related]
10. Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?
Amsden GW
J Antimicrob Chemother; 2005 Jan; 55(1):10-21. PubMed ID: 15590715
[TBL] [Abstract][Full Text] [Related]
11. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
Jones RN; Sader HS; Stilwell MG; Fritsche TR
Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904
[TBL] [Abstract][Full Text] [Related]
12. Single-dose azithromycin for respiratory tract infections.
Law C; Amsden GW
Ann Pharmacother; 2004 Mar; 38(3):433-9. PubMed ID: 14970367
[TBL] [Abstract][Full Text] [Related]
13. Azithromycin versus comparative therapy for the treatment of community acquired pneumonia.
Rahav G; Fidel J; Gibor Y; Shapiro M
Int J Antimicrob Agents; 2004 Aug; 24(2):181-4. PubMed ID: 15288319
[TBL] [Abstract][Full Text] [Related]
14. Chemoprophylactic effects of azithromycin against Rhodococcus equi-induced pneumonia among foals at equine breeding farms with endemic infections.
Chaffin MK; Cohen ND; Martens RJ
J Am Vet Med Assoc; 2008 Apr; 232(7):1035-47. PubMed ID: 18380623
[TBL] [Abstract][Full Text] [Related]
15. Traveler's diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen.
Tribble DR; Sanders JW; Pang LW; Mason C; Pitarangsi C; Baqar S; Armstrong A; Hshieh P; Fox A; Maley EA; Lebron C; Faix DJ; Lawler JV; Nayak G; Lewis M; Bodhidatta L; Scott DA
Clin Infect Dis; 2007 Feb; 44(3):338-46. PubMed ID: 17205438
[TBL] [Abstract][Full Text] [Related]
16. Clinical and economic outcomes in respiratory tract infections: The impact of bacterial resistance.
Rapp RP
Postgrad Med; 2002 Sep; 112(3 Suppl):12-7. PubMed ID: 19667590
[TBL] [Abstract][Full Text] [Related]
17. Is azithromycin prophylaxis a rational approach for bronchoscopic biopsy?
Karabay O
Respirology; 2007 Jul; 12(4):622; author reply 625. PubMed ID: 17587436
[No Abstract] [Full Text] [Related]
18. Antimicrobial treatment of lower respiratory tract infections in the hospital setting.
Grossman RF; Rotschafer JC; Tan JS
Am J Med; 2005 Jul; 118 Suppl 7A():29S-38S. PubMed ID: 15993675
[TBL] [Abstract][Full Text] [Related]
19. The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy.
Charles PG; Whitby M; Fuller AJ; Stirling R; Wright AA; Korman TM; Holmes PW; Christiansen KJ; Waterer GW; Pierce RJ; Mayall BC; Armstrong JG; Catton MG; Nimmo GR; Johnson B; Hooy M; Grayson ML;
Clin Infect Dis; 2008 May; 46(10):1513-21. PubMed ID: 18419484
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of bacterial resistance to macrolides.
Halpern MT; Schmier JK; Snyder LM; Asche C; Sarocco PW; Lavin B; Nieman R; Mandell LA
J Antimicrob Chemother; 2005 May; 55(5):748-57. PubMed ID: 15772147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
